Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing adverse facts about its priorities, particularly regarding capital allocation and a significant debt reduction strategy following the acquisition of Dermavant [3]. - The company’s regular quarterly dividend was reduced by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation to participate in the case [4]. Firm's Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation priorities following the acquisition of Dermavant [1][3]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - The suit alleges that after the acquisition, Organon shifted its focus to reducing debt rather than maintaining dividend payouts [3]. Stock Price Reaction - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, stating that returning capital to shareholders was a lower priority [4]. - Following this announcement, Organon's stock price fell by $3.48 per share, approximately 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4].

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lead ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and a significant reduction in quarterly dividends, which led to a sharp decline in stock price [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from October 31, 2024, to April 30, 2025 [2]. - Allegations include that Organon provided overly positive statements while concealing material adverse facts about its capital allocation priorities, particularly regarding debt reduction after the acquisition of Dermavant [2]. - Following the announcement of a 70% decrease in the regular quarterly dividend, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in one day [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 22, 2025, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for failing to disclose material information during the class period, which has led to significant financial repercussions for investors [3][4]. Group 1: Lawsuit Details - Investors have until July 22, 2025, to file lead plaintiff applications if they purchased Organon securities between October 31, 2024, and April 30, 2025 [1]. - The lawsuit is pending in the United States District Court for the District of New Jersey, under the case name Hauser V. Organon & Co., et al., No. 25-cv-05322 [5]. - The company and certain executives are accused of violating federal securities laws by not disclosing critical information during the class period [3]. Group 2: Financial Impact - On March 10, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors regarding the importance of maintaining the dividend [4]. - Following the announcement, Organon's share price dropped over 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4]. Group 3: Investor Support - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information on various cases [6]. - Investors can upload their portfolio data to receive notifications about relevant securities cases and can seek free case evaluations from the law firm Kahn Swick & Foti, LLC [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Organon between October 31, 2024 and April 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly making false and misleading statements regarding its capital allocation priorities and dividend payouts, leading to significant investor losses [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), and Rule 10b-5 [1]. - Investors who purchased Organon's securities between October 31, 2024, and April 30, 2025, are encouraged to participate in the lawsuit before the deadline of July 22, 2025 [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Organon - The complaint alleges that Organon concealed important information about its capital allocation priorities, particularly regarding its quarterly dividend payout [4]. - The company had previously reported that maintaining quarterly dividends was its "number one priority," which contradicted its debt reduction strategy, ultimately resulting in a 70% reduction in dividends [4]. - The misleading public statements made by Organon throughout the class period led to investor damages once the truth was revealed [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for failing to disclose material information, leading to significant financial losses for investors during the specified Class Period [3][4]. Group 1: Lawsuit Details - Investors who purchased Organon securities between October 31, 2024, and April 30, 2025, have until July 22, 2025, to file lead plaintiff applications [1][2]. - The lawsuit alleges that Organon and certain executives violated federal securities laws by not disclosing critical information during the Class Period [3]. Group 2: Financial Impact - On March 10, 2025, Organon announced a drastic reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors regarding the importance of maintaining the dividend [4]. - Following the announcement, Organon's share price plummeted over 27%, dropping from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4]. Group 3: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the investors in this case [5]. - The firm has a strong track record, being ranked among the top 10 firms nationally based on total settlement value [5].

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 through April 30, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants: (i) concealed material information pertain ...

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of over 70% in the quarterly dividend payout [4]. - Following the announcement of the reduced dividend from $0.28 to $0.02 on May 1, 2025, Organon's stock price fell by more than 27% [5]. Group 2: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - The company had previously reported optimistic dividend payouts as a priority, which were later contradicted by a new debt reduction strategy following its acquisition of Dermavant Sciences Ltd. [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].